> >Register Now <<

Speaker: Linda Carpenter, MD

Earlier this year, the FDA approved a novel home-use device for treatment of major depressive disorder in patients who have not responded to antidepressant medication. Available only with a prescription, Proliv™Rx is a wearable, at-home neurostimulation headset that uses non-invasive electrical pulses to stimulate the occipital and trigeminal nerves through surface electrodes.

Dr. Carpenter was the lead Principal Investigator for the large randomized controlled trial that generated efficacy and safety data for this device. She will present the data and describe how the ProLiv device will be used in future clinical practice.

Key learning objectives include:

• Evaluate the clinical trial data supporting efficacy and safety of a new home-use device for treatment of Major Depressive Disorder (MDD).
• Describe external combined occipital and trigeminal stimulation as a novel mechanism of action in the field of therapeutic neuromodulation.
• Discuss how the ProLiv Rx device is incorporated into clinical care as an adjunct therapy for MDD.

One CME credit is available.  CE Language

Take advantage of our live Q&A session at the conclusion of the webinar.

*Registered attendees will receive access to the on-demand video recording by Friday, May 8, 2026. You will receive an email notification with instructions on accessing the video. You may register for the on-demand webinar any time after the live webinar.

When:

USA - May 5, 2026 at 8:00pm ET | 5:00pm PT
UK- May 6, 2026 at 1:00am BST
Australia- May 6, 2026 at 10:00am AEST

Cost:

Member: $25
Trainee Member: FREE
Non-Member: $50

> >Register Now <<

About the Speaker

Linda Carpenter, MD
Dr. Carpenter has had nearly three decades of externally funded research focused on understanding biomarkers of early life stress and developing new treatments. She has expertise in clinical trials research involving pharmacotherapy and device-based neuromodulation treatments and has been PI on multiple industry- and NIH-funded randomized clinical trials, evaluating the safety and efficacy of both drug- and device-based therapies for depression and anxiety disorders. She has also conducted studies examining various mechanisms of therapeutic action and biomarkers of risk for psychiatric disorders.

For the past two decades, Dr. Carpenter's primary research focus has included therapeutic brain stimulation, and she has led numerous studies examining the efficacy, safety, and mechanisms of VNS, DBS, tDCS, TMS, and other neuromodulation devices in clinical populations.

Dr. Carpenter recently led the multi-center investigation of Proliv, a novel, FDA-cleared home-use device that delivers electrical trigeminal/occipital nerve stimulation for depression, and she is lead PI for a trial that uses fMRI-EEG-based neurofeedback for self-neuromodulation of a targeted depression circuit.

For the past 5 years Dr. Carpenter has also been developing methods for sustaining TMS antidepressant response over time with maintenance treatment and ecological momentary assessment.

Dr. Carpenter is the current Director of the CTMSS’s PULSES training course, and she serves on multiple other CTMSS committees.